{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:00:29Z","timestamp":1792839629931,"version":"4.5.0"},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,5,28]],"date-time":"2018-05-28T00:00:00Z","timestamp":1527465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Primary sclerosing cholangitis (<jats:styled-content style=\"fixed-case\">PSC<\/jats:styled-content>) is a chronic, progressive cholestatic biliary disease associated with inflammatory bowel disease (<jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content>) with no known cure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate the effect of biological therapies on <jats:styled-content style=\"fixed-case\">PSC<\/jats:styled-content> progression in <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a retrospective cohort study of 88 cases (75 unique patients with 12 patients treated &gt;1 biologics) of <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> (48 ulcerative colitis, 24 Crohn's disease and 3 indeterminate colitis) with concomitant <jats:styled-content style=\"fixed-case\">PSC<\/jats:styled-content> who received biological therapy (42 infliximab, 19 adalimumab, 27 vedolizumab) between June 2002 and October 2017. Hepatic biochemistries were compared using the paired <jats:italic>t<\/jats:italic>\u2010test (patients served as their own controls) \u22643\u00a0months before and 6\u20108 and 12\u201014\u00a0months after biological initiation. Radiographic information of biliary stenosis and liver fibrosis were obtained via abdominal ultrasound, abdominal magnetic resonance imaging and magnetic resonance elastography.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Use of adalimumab was associated with a significant decrease in alkaline phosphatase (<jats:styled-content style=\"fixed-case\">ALP<\/jats:styled-content>) after 6\u20108 months (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.03; mean change \u221270\u00a0U\/L, standard deviation [<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>] 88\u00a0U\/L) compared to vedolizumab (mean change +50\u00a0U\/L, <jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content> 142 U\/L) or infliximab (mean change +37 U\/L, <jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content> 183\u00a0U\/L) but the change was not significant after 12\u201014 months (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.24). No significant decreases were observed with <jats:styled-content style=\"fixed-case\">AST<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> ALT<\/jats:styled-content>, total or direct bilirubin, elastography score or radiographic imaging of biliary tree dilation\/strictures with any biological therapy after 6\u20108 or 12\u201014 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Current evidence suggests that biological therapies used for the treatment of <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> are not effective treatments for <jats:styled-content style=\"fixed-case\">PSC<\/jats:styled-content>. Further study is needed to elucidate any potential beneficial effect of adalimumab on <jats:styled-content style=\"fixed-case\">PSC<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.14829","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T04:25:00Z","timestamp":1527567900000},"page":"190-195","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease"],"prefix":"10.1111","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8847-4539","authenticated-orcid":false,"given":"C. S.","family":"Tse","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"E. V.","family":"Loftus","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. E.","family":"Raffals","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A.","family":"Gossard","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0459-0699","authenticated-orcid":false,"given":"A. L.","family":"Lightner","sequence":"additional","affiliation":[{"name":"Division of Colon and Rectal Surgery Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504063321406"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00872.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1040420"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2505"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.1.131"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1784"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.24231"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0176-2"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000847"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3181662426"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14525"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000596"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04822.x"},{"key":"e_1_2_7_15_1","first-page":"CD003626","article-title":"Bile acids for primary sclerosing cholangitis","author":"Poropat G","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_16_1","volume-title":"Goldman\u2010Cecil medicine","author":"Goldman L","year":"2016"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23294"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-012-0155-1"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2010.12.008"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.09.001"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2011.83"},{"key":"e_1_2_7_22_1","first-page":"209","article-title":"Pharmacokinetics of monoclonal antibodies used for inflammatory bowel diseases in pregnant women","volume":"4","author":"Stone RH","year":"2014","journal-title":"J Clin Toxicol"},{"key":"e_1_2_7_23_1","first-page":"1435","article-title":"Biologic concentration testing in inflammatory bowel disease","volume":"21","author":"Vaughn BP","year":"2015","journal-title":"Inflamm Bowel Dis"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.14829","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.14829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T09:52:41Z","timestamp":1694339561000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.14829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,28]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/apt.14829"],"URL":"https:\/\/doi.org\/10.1111\/apt.14829","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,28]]},"assertion":[{"value":"2018-03-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}